1. Scrip
  2. >>Business

Will Keytruda Price Differential Really Count In India?

 
• By Anju Ghangurde

Merck has launched Keytruda at an “India-specific” price but some experts say that the immuno-oncology therapy will likely still be beyond the reach of a majority of patients. Merck though also expects to offer a patient access program for those who can’t afford the therapy.

Cancer cell
KEYTRUDA HAS BEEN INTRODUCED AT AN INDIA-SPECIFIC PRICE • Source: Shutterstock

Merck & Co. Inc. has launched its breakthrough immuno-oncology therapy Keytruda (pembrolizumab) in India, putting the spotlight on the price tag that the PD-1 inhibitor comes with in a predominantly out-of-pocket market.

Merck did not share pricing details, other than to say that the product comes with an ‘India-specific price’ – an oft-used position by foreign firms which typically denotes a significant...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

ASCO: J&J Banks On T-Cell Engager’s Safety In Prostate Cancer

 
• By Andrew McConaghie

The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.

ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player

 
• By Alaric DeArment

The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.